Universidad Católica de Cuenca, Carrera de Medicina- Campus Cuenca, Cuenca, Ecuador
Universidad Católica de Cuenca, Carrera de Medicina- Campus Cuenca, Cuenca, Ecuador
Sociedad de Lucha contra el Cáncer, Guayaquil, Ecuador
Universidad Católica de Cuenca, Carrera de Medicina- Campus Cuenca, Cuenca, Ecuador
Introduction: Burkitt type lymphoma (BL) is one of the most common neoplasms in patients with HIV due to the immune compromise they present. BL patients who live with human immunodeficiency virus (HIV) have a survival rate of approximately 69% two years after diagnosis. However, other authors mention that survival is only 50%, in patients on antiretroviral treatment (ART) and chemotherapy, two years after diagnosis. BL occurs between 50% to 70% more in HIV-positive people and a low CD4 lymphocytes count increases the predisposition to develop BL. Chemotherapy is the method of choice for the treatment of Burkitt-type lymphoma in HIV-positive patients.
Objective: Determine the survival of patients diagnosed with Burkitt lymphoma in people living with human immunodeficiency virus
Methodology: Narrative bibliographic review. For the bibliographic search, information collected from the following databases was used: PubMed in conjunction with the application of Boolean operators: AND, OR, NOT; and with the help of search MeSH terms like, “Burkitt lymphoma”, AND “HIV” AND “Treatment”.
Results: Patients have a higher incidence of Burkitt-type lymphoma due to their immunosuppression, which is why it is important that they correctly adhere to antiretroviral treatment and chemotherapy, since the survival of these patients can be between 45% and 50%, two years after de diagnosis
Keywords: Burkitt Lymphoma, Treatment, HIV
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.